159 related articles for article (PubMed ID: 25010019)
1. Analgesic tolerance and cross-tolerance to the cannabinoid receptors ligands hemopressin, VD-hemopressin(α) and WIN55,212-2 at the supraspinal level in mice.
Pan JX; Wang ZL; Li N; Han ZL; Li XH; Tang HH; Wang P; Zheng T; Fang Q; Wang R
Neurosci Lett; 2014 Aug; 578():187-91. PubMed ID: 25010019
[TBL] [Abstract][Full Text] [Related]
2. Effects of the cannabinoid 1 receptor peptide ligands hemopressin, (m)RVD-hemopressin(α) and (m)VD-hemopressin(α) on memory in novel object and object location recognition tasks in normal young and Aβ1-42-treated mice.
Zhang RS; He Z; Jin WD; Wang R
Neurobiol Learn Mem; 2016 Oct; 134 Pt B():264-74. PubMed ID: 27481221
[TBL] [Abstract][Full Text] [Related]
3. Effects of neuropeptide FF and related peptides on the antinociceptive activities of VD-hemopressin(α) in naive and cannabinoid-tolerant mice.
Pan JX; Wang ZL; Li N; Zhang N; Wang P; Tang HH; Zhang T; Yu HP; Zhang R; Zheng T; Fang Q; Wang R
Eur J Pharmacol; 2015 Nov; 767():119-25. PubMed ID: 26472125
[TBL] [Abstract][Full Text] [Related]
4. Antinociceptive effects of central administration of the endogenous cannabinoid receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)], an N-terminally extended hemopressin peptide.
Han ZL; Fang Q; Wang ZL; Li XH; Li N; Chang XM; Pan JX; Tang HZ; Wang R
J Pharmacol Exp Ther; 2014 Feb; 348(2):316-23. PubMed ID: 24307201
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of rat VD-hemopressin(α), an α-hemoglobin-derived peptide exhibiting cannabinoid agonist-like effects in mice.
Zheng T; Zhang T; Zhang R; Wang ZL; Han ZL; Li N; Li XH; Zhang MN; Xu B; Yang XL; Fang Q; Wang R
Neuropeptides; 2017 Jun; 63():83-90. PubMed ID: 28010996
[TBL] [Abstract][Full Text] [Related]
6. CB
Zheng T; Zhang R; Zhang T; Zhang MN; Xu B; Song JJ; Li N; Tang HH; Wang P; Wang R; Fang Q
Brain Res; 2018 Feb; 1680():155-164. PubMed ID: 29274880
[TBL] [Abstract][Full Text] [Related]
7. Central administrations of hemopressin and related peptides inhibit gastrointestinal motility in mice.
Li XH; Lin ML; Wang ZL; Wang P; Tang HH; Lin YY; Li N; Fang Q; Wang R
Neurogastroenterol Motil; 2016 Jun; 28(6):891-9. PubMed ID: 26991932
[TBL] [Abstract][Full Text] [Related]
8. Antinociceptive effects of the endogenous cannabinoid peptide agonist VD-hemopressin(β) in mice.
Wang P; Zheng T; Zhang M; Xu B; Zhang R; Zhang T; Zhao W; Shi X; Zhang Q; Fang Q
Brain Res Bull; 2018 May; 139():48-55. PubMed ID: 29425797
[TBL] [Abstract][Full Text] [Related]
9. Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain.
Hama A; Sagen J
Brain Res; 2011 Sep; 1412():44-54. PubMed ID: 21813113
[TBL] [Abstract][Full Text] [Related]
10. VF-13, a chimeric peptide of VD-hemopressin(α) and neuropeptide VF, produces potent antinociception with reduced cannabinoid-related side effects.
Xu B; Xiao J; Xu K; Zhang Q; Chen D; Zhang R; Zhang M; Zhu H; Niu J; Zheng T; Li N; Zhang X; Fang Q
Neuropharmacology; 2020 Sep; 175():108178. PubMed ID: 32544481
[TBL] [Abstract][Full Text] [Related]
11. Neuropeptide VF Enhances Cannabinoid Agonist WIN55,212-2-Induced Antinociception in Mice.
Han ZL; Wang ZL; Li XH; Li N; Pan JX; Zheng T; Fang Q; Wang R
Anesth Analg; 2015 Nov; 121(5):1360-8. PubMed ID: 26273748
[TBL] [Abstract][Full Text] [Related]
12. Effects of neuropeptide FF system on CB₁ and CB₂ receptors mediated antinociception in mice.
Fang Q; Han ZL; Li N; Wang ZL; He N; Wang R
Neuropharmacology; 2012 Feb; 62(2):855-64. PubMed ID: 21945715
[TBL] [Abstract][Full Text] [Related]
13. CB1 Cannabinoid Agonist (WIN55,212-2) Within the Basolateral Amygdala Induced Sensitization to Morphine and Increased the Level of μ-Opioid Receptor and c-fos in the Nucleus Accumbens.
Molaei M; Fatahi Z; Zaringhalam J; Haghparast A
J Mol Neurosci; 2016 Apr; 58(4):446-55. PubMed ID: 26803309
[TBL] [Abstract][Full Text] [Related]
14. Intra-accumbal NMDA but not AMPA/kainate receptor antagonist attenuates WIN55,212-2 cannabinoid receptor agonist-induced antinociception in the basolateral amygdala in a rat model of acute pain.
Ghalandari-Shamami M; Hassanpour-Ezatti M; Haghparast A
Pharmacol Biochem Behav; 2011 Dec; 100(2):213-9. PubMed ID: 21924283
[TBL] [Abstract][Full Text] [Related]
15. Supraspinal interaction between HIV-1-gp120 and cannabinoid analgesic effectiveness.
Palma J; Narasimhan M; Guindon J; Benamar K
Naunyn Schmiedebergs Arch Pharmacol; 2018 Oct; 391(10):1157-1161. PubMed ID: 30008083
[TBL] [Abstract][Full Text] [Related]
16. Topical cannabinoid antinociception: synergy with spinal sites.
Dogrul A; Gul H; Akar A; Yildiz O; Bilgin F; Guzeldemir E
Pain; 2003 Sep; 105(1-2):11-6. PubMed ID: 14499415
[TBL] [Abstract][Full Text] [Related]
17. Tolerance to WIN55,212-2 is delayed in desensitization-resistant S426A/S430A mice.
Nealon CM; Henderson-Redmond AN; Hale DE; Morgan DJ
Neuropharmacology; 2019 Apr; 148():151-159. PubMed ID: 30629988
[TBL] [Abstract][Full Text] [Related]
18. Involvement of cannabinoid CB1 receptors in the antinociceptive effect of dipyrone.
Elmas P; Ulugol A
J Neural Transm (Vienna); 2013 Nov; 120(11):1533-8. PubMed ID: 23784345
[TBL] [Abstract][Full Text] [Related]
19. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
Sim-Selley LJ; Martin BR
J Pharmacol Exp Ther; 2002 Oct; 303(1):36-44. PubMed ID: 12235230
[TBL] [Abstract][Full Text] [Related]
20. The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice.
Dodd GT; Mancini G; Lutz B; Luckman SM
J Neurosci; 2010 May; 30(21):7369-76. PubMed ID: 20505104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]